Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 11, 2015, Pages H1846-H1859

  Brooks, Steven D ^a   De Vallance, Evan ^a   D’Audiffret, Alexandre C ^a   Frisbee, Stephanie J ^a   Tabone, Lawrence E ^a   Shrader, Carl D ^a   Frisbee, Jefferson C ^a   Chantler, Paul D ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Arterial stiffness; Cerebrovascular remodeling; Metabolic syndrome; Reactive oxygen species

Indexed keywords

ACETYLCHOLINE; ATORVASTATIN; CAPTOPRIL; GEMFIBROZIL; HYDRALAZINE; METFORMIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; ROSIGLITAZONE; TEMPOL; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; VASODILATOR AGENT;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN PERFUSION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE CEREBRAL ARTERY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RISK FACTOR; ZUCKER FATTY RAT; AGE; ANIMAL; BIOMECHANICS; BLOOD; BRAIN CIRCULATION; CEREBROVASCULAR DISORDERS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; OBESITY; PATHOPHYSIOLOGY; VASCULAR REMODELING; VASCULAR RESISTANCE; VASODILATATION; ZUCKER RAT;

AGE FACTORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BIOMECHANICAL PHENOMENA; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLAMMATION MEDIATORS; MALE; METABOLIC SYNDROME X; MIDDLE CEREBRAL ARTERY; NITRIC OXIDE; OBESITY; OXIDATIVE STRESS; RATS, ZUCKER; VASCULAR REMODELING; VASCULAR RESISTANCE; VASCULAR STIFFNESS; VASODILATION; VASODILATOR AGENTS;

EID: 84949310171     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00691.2015     Document Type: Article

References (55)

1. Aleixandre de Artinano A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. Br J Nutr 102: 1246–1253, 2009.
2. Andrews TC, Whitney EJ, Green G, Kalenian R, Personius BE. Effect of gemfibrozil ± niacin ± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol 80: 831–835, 1997.
3. Anonymous. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Professional, 2005.
4. Baumbach GL, Hajdu MA. Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension 21: 816–826, 1993.
5. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, Wright C, Giardina EG, DiTullio MR, Homma S, Paik MC.: Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 39: 30–35, 2008.
6. Butcher JT, Goodwill AG, Stanley SC, Frisbee JC. Differential impact of dilator stimuli on increased myogenic activation of cerebral and skeletal muscle resistance arterioles in obese Zucker rats. Microcirculation 20: 579–589, 2013.
7. Chantler P, Shrader CD, Tabone LE, d’Audiffret AC, Huseynova K, Brooks SD, Branyan KW, Grogg KA, Frisbee JC. Cerebral cortical microvascular rarefaction in metabolic syndrome is dependent on insulin resistance and loss of nitric oxide bioavailability. Microcirulation 22: 435–445, 2015.
8. Chantler PD, Frisbee JC. Arterial function in cardio-metabolic diseases: from the microcirculation to the large conduits. Prog Cardiovasc Dis 57: 489–496, 2015.
9. Chironi G, Simon A, Gariepy J, Balice M, Del-Pino M, Levenson J. Differential associations of statin and fibrate treatment with carotid arterial remodeling. Am J Hypertens 18: 1476–1481, 2005.
10. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103: 926–933, 2001.
11. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109: 339–343, 2004.
12. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 89: 740–747, 2004.
13. Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, Soininen H, Kivipelto M. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry 23: 741–747, 2008.
14. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, Klingman JG, Sidney S, Hills NK, Sorel M, Cullen SP, Johnston SC. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 43: 147–154, 2012.
15. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168: 351–358, 2003.
16. Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 289: R307–R316, 2005.
17. Frisbee JC, Maier KG, Stepp DW. Oxidant stress-induced increase in myogenic activation of skeletal muscle resistance arteries in obese Zucker rats. Am J Physiol Heart Circ Physiol 283: H2160–H2168, 2002.
18. Fukui K, Omoi NO, Hayasaka T, Shinnkai T, Suzuki S, Abe K, Urano S. Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Ann NY Acad Sci 959: 275–284, 2002.
19. Goodwill AG, Frisbee SJ, Stapleton PA, James ME, Frisbee JC. Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Microcirculation 16: 667–684, 2009.
20. Greenwood CE, Winocur G. Cognitive impairment in rats fed high-fat diets: a specific effect of saturated fatty-acid intake. Behav Neurosci 110: 451–459, 1996.
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 21: 1–6, 2006.
22. Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I, Tatematsu S, Kumagai H, Saruta T. Altered renal microvascular response in Zucker obese rats. Metab Clin Exp 51: 1553–1561, 2002.
23. Hodnett BL, Hester RL. Regulation of muscle blood flow in obesity. Microcirculation 14: 273–288, 2007.
24. Jarajapu YP, Guberski DL, Grant MB, Knot HJ. Myogenic tone and reactivity of cerebral arteries in type II diabetic BBZDR/Wor rat. Eur J Pharmacol 579: 298–307, 2008.
25. Jurdak N, Lichtenstein AH, Kanarek RB. Diet-induced obesity and spatial cognition in young male rats. Nutr Neurosci 11: 48–54, 2008.
26. Kanoski SE, Meisel RL, Mullins AJ, Davidson TL. The effects of energy-rich diets on discrimination reversal learning and on BDNF in the hippocampus and prefrontal cortex of the rat. Behav Brain Res 182: 57–66, 2007.
27. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 12: 311–318, 2007.
28. Kiyici S, Ersoy C, Kaderli A, Fazlioglu M, Budak F, Duran C, Gul OO, Sigirli D, Baran I, Tuncel E, Erturk E, Imamoglu S. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract 86: 44–50, 2009.
29. Kuklinska AM, Mroczko B, Musial WJ, Sawicki R, Kozieradzka A, Usowicz-Szarynska M, Kaminski K, Knapp M, Szmitkowski M. Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients: an open, pilot study. Blood Pressure 19: 260–266, 2010.
30. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. I. Aging arteries: a “set up” for vascular disease. Circulation 107: 139–146, 2003.
31. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13: 221–228, 2011.
32. Liu M, Wang F, Wang Y, Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther 23: 369–376, 2009.
33. Lombard JH, Liu Y, Fredricks KT, Bizub DM, Roman RJ, Rusch NJ. Electrical and mechanical responses of rat middle cerebral arteries to reduced PO2 and prostacyclin. Am J Physiol Heart Circ Physiol 276: H509–H516, 1999.
34. Lu D, Mahmood A, Goussev A, Schallert T, Qu C, Zhang ZG, Li Y, Lu M, Chopp M. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg 101: 813–821, 2004.
35. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 15: 321–325, 2002.
36. Martinez-Lemus LA, Zhao G, Galinanes EL, Boone M. Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases. Am J Physiol Heart Circ Physiol 300: H2005–H2015, 2011.
37. Matrougui K. Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev 26: 13–16, 2010.
38. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Dietary fat intake and 6-year cognitive change in an older biracial community population. Neurology 62: 1573–1579, 2004.
39. Osmond JM, Mintz JD, Dalton B, Stepp DW. Obesity increases blood pressure, cerebral vascular remodeling, and severity of stroke in the Zucker rat. Hypertension 53: 381–386, 2009.
40. Osmond JM, Mintz JD, Stepp DW. Preventing increased blood pressure in the obese Zucker rat improves severity of stroke. Am J Physiol Heart Circ Physiol 299: H55–H61, 2010.
41. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, D’Onofrio G, Seripa D, Sancarlo D, Pilotto A, Solfrizzi V. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 21: 691–724, 2010.
42. Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and hypertension: emerging concepts. Hypertension 55: 9–14, 2010.
43. Phillips SA, Sylvester FA, Frisbee JC. Oxidant stress and constrictor reactivity impair cerebral artery dilation in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 288: R522–R530, 2005.
44. Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol 304: H1598–H1614, 2013.
45. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, Portet F, Dartigues JF, Alperovitch A, Barberger-Gateau P. Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City Study. Diabetes Care 32: 169–174, 2009.
46. Roberts RO, Geda YE, Knopman DS, Cha RH, Boeve BF, Ivnik RJ, Pankratz VS, Tangalos EG, Petersen RC. Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord 24: 11–18, 2010.
47. Sardone LD, Renlund R, Willett TL, Fantus IG, Grynpas MD. Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes 60: 3271–3278, 2011
48. Solfrizzi V, Scafato E, Capurso C, D’Introno A, Colacicco AM, Frisardi V, Vendemiale G, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Capurso A, Panza F, Italian Longitudinal Study on Ageing Working Group. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 81: 433–440, 2010.
49. Stabley JN, Prisby RD, Behnke BJ, Delp MD. Type 2 diabetes alters bone and marrow blood flow and vascular control mechanisms in the ZDF rat. J Endocrinol 225: 47–58, 2015.
50. Stocker R, Keaney JF Jr.. Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381–1478, 2004.
51. Tucsek Z, Toth P, Tarantini S, Sosnowska D, Gautam T, Warrington JP, Giles CB, Wren JD, Koller A, Ballabh P, Sonntag WE, Ungvari Z, Csiszar A. Aging exacerbates obesity-induced cerebromicrovascular rarefaction, neurovascular uncoupling, and cognitive decline in mice. J Gerontol A Biol Sci Med Sci 69: 1339–1352, 2014.
52. Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 88: 3212–3217, 2003.
53. Wessels B, Ciapaite J, van den Broek NM, Nicolay K, Prompers JJ. Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner. PLos One 9: e100525, 2014.
54. Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP, McEwen BS. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci 119: 1389–1395, 2005.
55. Zhang L, Wei WS, Li YJ, Wang Y. A rat model of mild cognitive impairment associated with vascular factor. Neuropathology 31: 112–121, 2011.